West Oak Capital LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

West Oak Capital LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% in the 3rd quarter, Holdings Channel reports. The firm owned 17,822 shares of the company’s stock after selling 1,275 shares during the period. Johnson & Johnson accounts for approximately 1.4% of West Oak Capital LLC’s holdings, making the stock its 22nd biggest position. West Oak Capital LLC’s holdings in Johnson & Johnson were worth $2,306,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zions Bancorporation N.A. increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after purchasing an additional 73 shares in the last quarter. Vishria Bird Financial Group LLC increased its stake in shares of Johnson & Johnson by 3.0% in the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after purchasing an additional 80 shares in the last quarter. Burt Wealth Advisors increased its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock worth $1,665,000 after purchasing an additional 82 shares in the last quarter. Deane Retirement Strategies Inc. increased its stake in shares of Johnson & Johnson by 0.7% in the second quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock worth $1,724,000 after purchasing an additional 85 shares in the last quarter. Finally, Evanson Asset Management LLC increased its stake in shares of Johnson & Johnson by 0.5% in the second quarter. Evanson Asset Management LLC now owns 17,870 shares of the company’s stock worth $2,489,000 after purchasing an additional 85 shares in the last quarter. 72.01% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:JNJ traded down $0.67 during midday trading on Thursday, reaching $131.33. 3,590,417 shares of the company were exchanged, compared to its average volume of 6,210,075. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The business’s fifty day moving average is $129.81 and its two-hundred day moving average is $135.22. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The stock has a market cap of $341.46 billion, a PE ratio of 16.06, a price-to-earnings-growth ratio of 2.19 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the prior year, the business earned $2.10 earnings per share. Johnson & Johnson’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 8.6 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $0.95 per share. The ex-dividend date was Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio is 46.45%.

JNJ has been the subject of a number of analyst reports. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Bank of America reissued a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective for the company. in a research note on Thursday, July 18th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and an average price target of $150.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Monthly Dividend Stocks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.